Levodopa-Carbidopa Intestinal Gel Monotherapy: GLORIA Registry Demographics, Efficacy, and Safety
Authors:
Open Access
- 29 June 2019
- journal article
- research article
- Published by SAGE Publications in Journal of Parkinson’s Disease
- Vol. 9 (3) , 531-541
Abstract
Background: Continuous delivery of levodopa-carbidopa intestinal gel (LCIG) provides stable plasma levodopa concentrations and reduces motor fluctuations in advanced Parkinson’s disease (PD) patients. Objective: To compare the effectiveness and safety of LCIG monotherapy vs polytherapy in patients in the GLORIA registry. Methods: This was a post hoc analysis of a 24-month, multinational observational registry where advanced PD patients with persistent motor complications received LCIG (with adjunctive PD treatment, as necessary). Patients were categorized retrospectively into three stable treatment groups: LCIG monotherapy, LCIG in combination with oral levodopa only (“levodopa monotherapy” [including nighttime oral levodopa]), or LCIG in combination with any other antiparkinsonian medication (“LCIG polytherapy”). Results: Of 356 patients, 208 were on stable regimens (LCIG monotherapy n = 80; levodopa monotherapy n = 47; LCIG polytherapy n = 81). Baseline characteristics were similar across groups. LCIG monotherapy showed significant improvements until month 18 in activities of daily living and quality of life, and until month 24 for Unified Parkinson’s Disease Rating Scale (UPDRS) motor examination ( p < 0.05), “Off” time ( p < 0.001), “On” time with dyskinesia ( p < 0.01), and non-motor symptoms ( p < 0.01). More patients in the levodopa monotherapy and LCIG polytherapy groups experienced treatment-related adverse drug reactions (ADRs) including dyskinesias and serious ADRs than did patients in the LCIG monotherapy group. There were few polyneuropathy-related ADRs, of which one case of polyneuropathy led to discontinuation from the Levodopa monotherapy group. Conclusions: These data demonstrate that LCIG monotherapy is an effective treatment option in appropriate advanced PD patients; however, definitive baseline clinical predictors identifying patients who can discontinue concomitant oral therapy have not yet been defined.Keywords
This publication has 15 references indexed in Scilit:
- Global long-term study on motor and non-motor symptoms and safety of levodopa-carbidopa intestinal gel in routine care of advanced Parkinson's disease patients; 12-month interim outcomesParkinsonism & Related Disorders, 2015
- Medication Adherence in Patients with Parkinson’s DiseaseCNS Drugs, 2014
- Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy studyThe Lancet Neurology, 2014
- Medication Nonadherence in Parkinson’s DiseaseCurrent Neurology and Neuroscience Reports, 2013
- Systematic review on factors associated with medication non-adherence in Parkinson's diseaseParkinsonism & Related Disorders, 2012
- Determination of minimal clinically important change in early and advanced Parkinson's diseaseMovement Disorders, 2011
- Role of Pramipexole in the Management of Parkinsonʼs DiseaseCNS Drugs, 2010
- Prevalence and cost of medication nonadherence in Parkinson's disease: Evidence from administrative claims dataMovement Disorders, 2010
- Levodopa: Past, Present, and FutureEuropean Neurology, 2008
- Suboptimal medication adherence in Parkinson's diseaseMovement Disorders, 2005